Fatal adverse drug reactions of anticancer drugs detected by all-case post-marketing surveillance in Japan.

about

Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit.

P2860

Q38501976-B73FFB4E-3841-4A94-B229-4C2A2316ED94

P2860

Fatal adverse drug reactions of anticancer drugs detected by all-case post-marketing surveillance in Japan.

Item

http://www.wikidata.org/entity/Q50949890

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Fatal adverse drug reactions o ...... rketing surveillance in Japan.

@en

Fatal adverse drug reactions o ...... rketing surveillance in Japan.

@nl

type

Item

label

Fatal adverse drug reactions o ...... rketing surveillance in Japan.

@en

Fatal adverse drug reactions o ...... rketing surveillance in Japan.

@nl

prefLabel

Fatal adverse drug reactions o ...... rketing surveillance in Japan.

@en

Fatal adverse drug reactions o ...... rketing surveillance in Japan.

@nl

P1476

Fatal adverse drug reactions o ...... rketing surveillance in Japan.

@en

P2093

Jinichi Mori

http://www.w3.org/2001/XMLSchema#string

Masahiro Kami

http://www.w3.org/2001/XMLSchema#string

Tetsuya Tanimoto

http://www.w3.org/2001/XMLSchema#string

Yuji Miura

http://www.w3.org/2001/XMLSchema#string

P2860

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer

Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer.

Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.

Pharmacogenetics and pharmacogenomics of anticancer agents.

Under-reporting of adverse drug reactions : a systematic review.

Pharmacovigilance: methods, recent developments and future perspectives.

Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight.

Postmarketing surveillance and adverse drug reactions: current perspectives and future needs.

P304

588-594

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JJCO/HYV030

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-03-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25759486

http://www.w3.org/2001/XMLSchema#string

Fatal adverse drug reactions of anticancer drugs detected by all-case post-marketing surveillance in Japan.

about

P2860

P2860

Fatal adverse drug reactions of anticancer drugs detected by all-case post-marketing surveillance in Japan.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698